Search Patents
  • SINGLE DOMAIN ANTIBODIES THAT TARGET SARS-COV-2
    Publication number: 20230374116
    Abstract: The present invention relates to improved single domain antibodies that target SARS-CoV-2, multivalent polypeptides and fusion proteins comprising the single domain antibodies. The present invention also provides coronavirus binding molecules that bind two different epitopes on the receptor binding domain of a spike protein of a coronavirus. The coronavirus binding molecules are based on joining two antigen binding molecules together via a linker. The present invention provides the use of said single domain antibodies, multivalent polypeptides, fusion proteins and coronavirus binding molecules in treating and/or preventing coronavirus, as well as the use of said single domain antibodies, multivalent polypeptides, fusion proteins and coronavirus binding molecules in the detection and diagnosis of coronavirus using various methods, assays and kits.
    Type: Application
    Filed: September 14, 2021
    Publication date: November 23, 2023
    Inventors: Jiandong Huo, Raymond Owens, James Naismith
  • COMPOSITIONS AND METHODS FOR DIAGNOSING SARS-COV-2 (COVID-19) AND FOR MONITORING SARS-COV-2-SPECIFIC IMMUNOLOGICAL MEMORY
    Publication number: 20240027450
    Abstract: Compositions and methods are provided for detection, diagnosis and prognosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) and for characterization of SARS-CoV-2 antigen-specific T-cell immune responsiveness in COVID-19 patient samples, including in secondary in vitro immune response assays for long-lived anamnestic (memory) T-cell responses. Disclosed compositions and methods include a method that comprises contacting, in vitro, whole blood samples from subjects suspected of having COVID-19 or who have previously been exposed to SARS-CoV-2, with synthetic peptides comprising T-cell epitope-containing regions derived from SARS-CoV-2 Spike proteins; and indirectly detecting SARS-CoV-2-specific activated T-cells by determining production of a T-cell immune response indicator (e.g., interferon-?) in response to stimulation by the Spike protein-derived peptides.
    Type: Application
    Filed: December 3, 2021
    Publication date: January 25, 2024
    Inventors: Jeff BOYLE, Jenny HOWARD, Soumya JAGANATHAN, Dave LEWINSOHN, Deborah LEWINSOHN, Gwendolyn SWARBRICK
  • METHODS AND COMPOSITIONS FOR DETECTING AND PRODUCING PORCINE MORBILLIVIRUS AND VACCINES THEREOF
    Publication number: 20240139306
    Abstract: Disclosed herein are methods for detecting and producing PoMV. Further, disclosed herein are immunogenic and/or vaccine compositions and methods for treating or preventing PoMV. The compositions and methods include immunogenic portions of PoMV including entry proteins. In at least particular cases, a mutated version of a portion of the PoMV is utilized, such as a deglycosylated, or amino acid substituted mutant of the spike protein.
    Type: Application
    Filed: March 1, 2022
    Publication date: May 2, 2024
    Inventors: Ganwu Li, Bailey Arruda, Huigang Shen, Ying Zheng
  • COVID-19 VACCINE
    Publication number: 20210300970
    Abstract: Provided herein are antigenic peptides comprising the SARS-CoV-2 spike protein receptor binding domain (CRBD) polypeptide or portions thereof, linked to a non-catalytic, non-toxic tetanus toxin variant (i.e., a modified tetanus toxin or “MTT”) and vaccine compositions comprising the same. In addition, provided herein are methods for making and using CRBD-MTT fusion proteins as immunogenic agents.
    Type: Application
    Filed: March 24, 2021
    Publication date: September 30, 2021
    Inventors: Joseph T. Barbieri, Amanda Przedpelski, Eric A. Johnson, Sabine Pellett, William H. Tepp
  • COMPOSITIONS FOR PREVENTING OR TREATING VIRAL AND OTHER MICROBIAL INFECTIONS
    Publication number: 20220119501
    Abstract: The present application relates to compositions for preventing or treating viral and other microbial infections. In some embodiments, the present application provides chimeric proteins comprising a target-binding moiety that specifically binds to a pathogen that infects through a mucosa, and a positively charged mucoadhesive peptide fragment. Also provided are antibodies and constructs thereof that specifically binds to an S1 subunit of a spike protein of SARS-CoV-2. Compositions comprising the chimeric proteins, antibodies, or constructs described herein are useful for preventing or treating a microbial infection in an individual, such as a coronavirus infection.
    Type: Application
    Filed: October 14, 2021
    Publication date: April 21, 2022
    Inventors: Cheng LIU, Hongbing ZHANG, Zhiyuan YANG, Jingyi XIANG, Ziyou CUI, Jianying LIU
  • COMPOSITIONS FOR PREVENTING OR TREATING VIRAL AND OTHER MICROBIAL INFECTIONS
    Publication number: 20230141962
    Abstract: The present application relates to compositions for preventing or treating viral and other microbial infections. In some embodiments, the present application provides chimeric proteins comprising a target-binding moiety that specifically binds to a pathogen that infects through a mucosa, and a positively charged mucoadhesive peptide fragment. Also provided are antibodies and constructs thereof that specifically binds to an S1 subunit of a spike protein of SARS-CoV-2. Compositions comprising the chimeric proteins, antibodies, or constructs described herein are useful for preventing or treating a microbial infection in an individual, such as a coronavirus infection.
    Type: Application
    Filed: August 4, 2022
    Publication date: May 11, 2023
    Inventors: Cheng LIU, Hongbing Zhang, Zhiyuan Yang, Jingyi Xiang, Ziyou Cui, Jianying Liu
  • SINGLE-DOMAIN ANTIBODIES THAT BIND SARS-COV-2
    Publication number: 20230331824
    Abstract: Single-domain antibodies that bind the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) spike protein are disclosed. The single-domain antibodies include binding domains that bind epitopes of the Spike ectodomain inside and outside the receptor binding domain. The single-domain antibodies can be used for multiple purposes including in the research, diagnosis, and prophylactic or therapeutic treatment of COVID-19.
    Type: Application
    Filed: August 20, 2021
    Publication date: October 19, 2023
    Applicants: The Rockefeller University, Seattle Children's Hospital d/b/a Seattle Children's Research Institute, New York University
    Inventors: Brian T. Chait, Michael P. Rout, John Aitchison, Fred David Mast, Jean Paul Olivier, David Fenyo
  • VACCINE COMPOSITION FOR PREVENTION OR TREATMENT OF SARS-CORONAVIRUS-2 INFECTION
    Publication number: 20240042008
    Abstract: The present invention provides a recombinant antigen protein for preventing SARS-coronavirus-2 infection, comprising a polypeptide derived from an S1 subunit of a spike protein of SARS-coronavirus-2 and a polypeptide constituting a tetanus toxin (TT) epitope P2 domain, and a vaccine composition comprising the same.
    Type: Application
    Filed: October 27, 2021
    Publication date: February 8, 2024
    Applicant: SK BIOSCIENCE CO., LTD.
    Inventors: Ki-weon SEO, Teawoo KWON, Eun-som KIM, Chi-Yong KIM, Yoonjae LEE, Seung-hye HONG
  • CORONAVIRUS DISEASE (COVID-19) VACCINE
    Publication number: 20230338513
    Abstract: The present invention includes a vaccine comprising a SARS-CoV-2 spike protein (S) or portion thereof, and methods of use thereof.
    Type: Application
    Filed: March 20, 2023
    Publication date: October 26, 2023
    Inventors: Matthias Johannes Schnell, Christoph Wirblich, Drishya Kurup
  • SARS-COV-2 CHIMERIC VLP VACCINE COMPOSITION, EXPRESSING VECTOR AND USE THEREOF
    Publication number: 20230058789
    Abstract: The present invention provides a SARS-CoV-2 chimeric VLP vaccine composition and an expressing vector and use thereof. The chimeric SARS-CoV-2 VLP comprises a VLP skeleton formed by the M1 protein and the M2 protein of influenza virus, and the chimeric spike protein of SARS-CoV-2, expressed on the surface of the VLP skeleton, the transmembrane domain of which is replaced by the transmembrane domain of a HA of influenza virus. The present invention also provides a recombinant vector expressing the chimeric SARS-CoV-2 VLP, and the use of the chimeric SARS-CoV-2 VLP for eliciting an immune response against SARS-CoV-2 variants.
    Type: Application
    Filed: August 1, 2022
    Publication date: February 23, 2023
    Inventors: SUH CHIN WU, Wei Shuo Lin, Ting Hsuan Chen
  • CORONAVIRUS DISEASE (COVID-19) VACCINE
    Publication number: 20230057428
    Abstract: The present invention includes a vaccine comprising a SARS-CoV-2 spike protein (S) or portion thereof, and methods of use thereof.
    Type: Application
    Filed: August 5, 2022
    Publication date: February 23, 2023
    Inventors: Matthias Johannes SCHNELL, Christoph WIRBLICH, Drishya KURUP
  • Vaccine compositions for the treatment of coronavirus
    Patent number: 11253587
    Abstract: The present disclosure provides compositions and methods useful for preventing and/or treating coronavirus infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more coronavirus epitopes, such as, for example, from SARS-Cov-2 spike protein.
    Type: Grant
    Filed: March 30, 2021
    Date of Patent: February 22, 2022
    Assignee: Variation Biotechnologies Inc.
    Inventors: David Evander Anderson, Anne-Catherine Fluckiger
  • CORONAVIRUS-DERIVED RECEPTOR-BINDING DOMAIN VARIANT HAVING REDUCED ACE2-BINDING AFFINITY AND VACCINE COMPOSITION COMPRISING THE SAME
    Publication number: 20230355745
    Abstract: Disclosed are a novel coronavirus-derived receptor-binding domain variant having reduced ACE2-binding affinity, a fusion protein comprising the same, and the use thereof. It is possible to overcome the drawbacks of conventional vaccines using the coronavirus spike protein or receptor-binding domain thereof, wherein the reduced ACE2 expression due to binding to ACE2 and negative feedback may lead to side effects of the lungs or heart, and in particular, may be fatal to patients suffering from underlying diseases of the lungs or heart. In particular, the fusion protein constructed by fusing the coronavirus receptor-binding domain with the Fc domain is imparted with a greatly improved in-vivo half-life, and has superior efficacy by further combining N protein, M protein, ORF protein, or the like of SARS-CoV-2 therewith through additional modification and thus is highly applicable to a multivalent immunogenic composition.
    Type: Application
    Filed: January 29, 2021
    Publication date: November 9, 2023
    Inventors: Myoung Ho JANG, Jae Chan PARK, Young Joo CHOI, Young Hyun PARK, Gil-Jung KIM, Seung Mi JEONG, Yeon Soo PARK, Su Bin LEE
  • MULTI-PROLINE-SUBSTITUTED CORONAVIRUS SPIKE PROTEIN VACCINES
    Publication number: 20230355743
    Abstract: The disclosure provides coronavirus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: September 24, 2021
    Publication date: November 9, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Guillaume Stewart-Jones, Mihir Metkar, Vladimir Presnyak
  • COMPUTATIONALLY-OPTIMIZED ACE2 PEPTIDES FOR COMPETITIVE INTERCEPTION OF SARS-CoV-2
    Publication number: 20220002700
    Abstract: Methods and compositions relating to an engineered peptide capable of binding to a biological molecule for viral inhibition. The engineered peptide is computationally-derived from soluble angiotensin-converting enzyme 2 (sACE2), a known receptor for viral spike proteins. The engineered peptide is optimized for minimal size and off-target effects. The engineered sACE2 peptide variants are a suitable targeting domain for fusion proteins of various effects.
    Type: Application
    Filed: April 5, 2021
    Publication date: January 6, 2022
    Inventors: Pranam CHATTERJEE, Raghava Manvitha PONNAPATI, Eyal PERRY, Joseph M. JACOBSON
  • SARS-COV2 VACCINE VECTOR METHODS AND COMPOSITIONS
    Publication number: 20220048954
    Abstract: Provided herein are recombinant nucleic acids and viral vectors thereof encoding a SARS-CoV-2 spike protein that have been optimized for expression in mammalian cells.
    Type: Application
    Filed: April 26, 2021
    Publication date: February 17, 2022
    Inventors: Gerald Pao, Junko Ogawa
  • ACE2 COMPOSITIONS AND METHODS
    Publication number: 20230257726
    Abstract: This disclosure describes recombinant angiotensin-converting enzyme II (ACE2) polypeptides, fusion proteins, and compositions thereof having improved binding affinity for the SARS-CoV-2 spike protein receptor binding domain relative to wild-type ACE2. Also provided are methods of using the recombinant ACE2 polypeptides, fusion proteins, and compositions thereof for treating subjects infected with a SARS-CoV-2 virus (i.e., subjects with COVID-19), subjects having symptoms suggestive of a SARS-CoV-2 infection, and subjects exposed to or at risk of exposure to SARS-CoV-2 virus. Other virus infections may also be treated.
    Type: Application
    Filed: May 11, 2021
    Publication date: August 17, 2023
    Inventors: Anum Glasgow, Jeff Glasgow, James A. Wells, Xin Zhou, Tanja Kortemme, Irene Lui
  • Compositions for preventing or treating viral and other microbial infections
    Patent number: 11440952
    Abstract: The present application relates to compositions for preventing or treating viral and other microbial infections. In some embodiments, the present application provides chimeric proteins comprising a target-binding moiety that specifically binds to a pathogen that infects through a mucosa, and a positively charged mucoadhesive peptide fragment. Also provided are antibodies and constructs thereof that specifically binds to an S1 subunit of a spike protein of SARS-CoV-2. Compositions comprising the chimeric proteins, antibodies, or constructs described herein are useful for preventing or treating a microbial infection in an individual, such as a coronavirus infection.
    Type: Grant
    Filed: October 14, 2021
    Date of Patent: September 13, 2022
    Assignee: InvisiShield Technologies Ltd.
    Inventors: Cheng Liu, Hongbing Zhang, Zhiyuan Yang, Jingyi Xiang, Ziyou Cui, Jianying Liu
  • MULTIGENIC MVA-SARS-COV-2 VACCINE
    Publication number: 20220370600
    Abstract: The present invention includes compositions and methods of making and using an immunogenic protein for mucosal delivery comprising at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% amino acid identity to a multigenic coronavirus vaccine on a modified vaccinia ankara (MVA) vector that expresses a viral nucleoprotein (N) protein and a spike (S) protein.
    Type: Application
    Filed: May 18, 2022
    Publication date: November 24, 2022
    Inventors: Haitao HU, Chaojie Zhong
  • Coronavirus disease (COVID-19) vaccine
    Patent number: 11478543
    Abstract: The present invention includes a vaccine comprising a SARS-CoV-2 spike protein (S) or portion thereof, and methods of use thereof.
    Type: Grant
    Filed: March 5, 2021
    Date of Patent: October 25, 2022
    Assignee: Thomas Jefferson University
    Inventors: Matthias J. Schnell, Christoph Wirblich, Drishya Kurup
Narrow Results

Filter by US Classification